Anti cancer drugs in pulmonary arterial hypertension

Pulmonary vascular remodeling of lung arteries plays an important role in the pathogenesis of pulmonary arterial hypertension (PAH). This leads to an accumulation of cells in the vessel wall and to a reduced vascular lumen. New therapeutic approaches try to reduce the benign proliferation and attempt to reverse the remodeling of the pulmonary arteries using anti-cancer drugs. In the focus of our interest are inhibitors of tyrosine-kinases, which showed promising effects in preclinical models of pulmonary hypertension and first clinical studies.